O.V. Knyazev, A.V. Kagramanova, I.A. Korneeva, K.K. Noskova, S.V. Belousov, A.I. Parfenov

• Published in: Terapevtic̆eskii arhiv Vol. 91; no. 4; pp. 53 - 61
• Main Authors: Knyazev, O V, Kagramanova, A V, Korneeva, I A, Noskova, K K, Belousov, S V, Parfenov, A I
• Format: Journal Article
• Language: English
• Published: "Consilium Medicum" Publishing house 15.04.2019
• Subjects: crohn disease; fecal calprotectin; inflammatory bowel diseases; ulcerative colitis
• ISSN: 0040-3660; 2309-5342
• DOI: 10.26442/00403660.2019.04.000229

Aim. To compare fecal calprotectin (FC) concentration with laboratory and diagnostic methods in patients with inflammatory bowel diseases (IBD). Materials and methods. The level of FC was measured in 110 patients with established IBD. Crohn diseases (CD) was diagnosed in 50 patients, ileocolitis - in 38 and terminal ileitis in 12 individuals. Ulcerative colitis (UC) was diagnosed in 60 patients, total colitis in 35, left-side colitis in 21 and 4 patients have proctitis. Laboratory data include measurement of FC, leukocytes, erythrocyte sedimentation rate (ESR), C reactive protein (CRP), fecal occult blood. All patients underwent colonoileoscopy (CIS) at the start of disease flare and after 12 weeks of treatment. Results and discussion. We found linear correlation between level of FCP and endoscopic activity of CD, analyzing FCP level and endoscopic activity of CD before (during disease flare) and after 12 weeks treatment (r=0.66, p